OakChart

Rocket Pharmaceuticals Inc

RCKTHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

2.48+0.03 (1.22%)
2026-11-11 22:08 CET
Market cap
268.95 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-17.25 USD m
Free cash flow, TTM
-170.40 USD m
EPS diluted, TTM
-0.18
P/E
-
Compare

Price

RCKT against its 20, 50 and 200-day averages
2050200beat
2.503.003.504.005.6M11.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RCKTclose 2.4820-day 2.4050-day 2.77200-day 3.402.4852w low

54.5% under the 52-week high of 5.45 on 10 Mar 2026. 52-week low 2.17 on 19 Oct 2026. Last 15 sessions, 23.0% high to low

Volume 0.53× normal · the line is the 50-bar volume average

Profile

RCKT
52-week range, 10% of the way up
2.165.45

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The firm's multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

IndexRUT
Employees202
IPOFeb 18, 2015
Beta0.48
ATR, 14d0.19
Rel volume0.53
Short float15.67%
Insider own5.57%
Inst own87.29%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap272.24M
Enterprise Value13.29M
Income-17.25M
Sales0.00M
Book/sh3.37
Cash/sh2.58
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees202
IPOFeb 18, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.74
P/C0.96
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio9.24
Current Ratio9.24
Debt/Eq0.07
LT Debt/Eq0.06
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.18
EPS next Y-1.36
EPS next Q-0.40
EPS this Y93.53%
EPS next Y-949.20%
EPS next 5Y18.58%
EPS past 3/5Y14.88% 4.46%
Sales past 3/5Y- -
EPS Y/Y TTM93.45%
Sales Y/Y TTM-
EPS Q/Q273.32%
Sales Q/Q-
EarningsAug 10 AMC
EPS/Sales Surpr.25.58% -100.00%

Ownership

Insider Own5.57%
Insider Trans-4.13%
Inst Own87.29%
Inst Trans0.47%
ROA-4.09%
ROE-4.77%
ROIC-4.42%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA203.16%
SMA50-10.57%
SMA200-27.12%
Trades-

Technical

Shs Outstand109.54M
Shs Float103.66M
Short Float15.67%
Short Ratio8.99
Short Interest16.24M
52W High5.45 -54.50%
52W Low2.16 14.55%
Volatility9.17% 8.15%
ATR (14)0.19
RSI (14)48.10
Beta0.48
Rel Volume0.53
Avg Volume1.81M
Volume962,725

Performance

Perf Week-4.98%
Perf Month7.83%
Perf Quarter-25.75%
Perf Half Y-31.11%
Perf YTD-29.34%
Perf Year-23.93%
Perf 3Y-86.63%
Perf 5Y-92.90%
Perf 10Y-91.21%
Recom2.14
Target Price8.58
Prev Close2.45
Price2.48
Change %1.22%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 08, 2026UpgradeGGoldmanSell → Neutral$4+61.3%
Sep 16, 2026UpgradeNNeedhamHold → Buy$9+262.9%
Sep 01, 2026ResumedCChardan Capital MarketsBuy$11+343.5%
Nov 18, 2025DowngradeJJP MorganNeutral → Underweight
Aug 20, 2025UpgradeBBofA SecuritiesNeutral → Buy$10+303.2%
Jul 25, 2025DowngradeBBofA SecuritiesBuy → Neutral$4+61.3%
May 30, 2025DowngradeEEvercore ISIOutperform → In-line$5+101.6%
May 28, 2025DowngradeMMorgan StanleyOverweight → Equal-Weight$7+182.3%
May 28, 2025DowngradeLLeerink PartnersOutperform → Market Perform$8+222.6%
May 28, 2025DowngradeJJP MorganOverweight → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
LXEOLexeo Therapeutics Inc252.01M
TNYATenaya Therapeutics Inc84.61M
RGNXRegenxbio Inc560.06M
SLDBSolid Biosciences Inc848.24M
SRPTSarepta Therapeutics Inc1.79B
FDMT4D Molecular Therapeutics Inc717.62M
ABEOAbeona Therapeutics Inc131.44M
QUREuniQure NV1.72B
MGTXMeiraGTx Holdings plc929.69M
BEAMBeam Therapeutics Inc2.67B

Insider trading

latest 14 of 62
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Wilson MartinGeneral CounselNov 05 '26Sale2.3953,389127,813545,100Nov 09 04:05 PM
Stevens Christopher JamesOfficerNov 09 '26Proposed Sale2.3316,13137,530Nov 09 03:23 PM
Chaudhuri SarbaniOfficerNov 09 '26Proposed Sale2.334,87211,335Nov 09 03:20 PM
Wilson MartinOfficerNov 05 '26Proposed Sale2.3953,389127,808Nov 05 03:10 PM
Wilson MartinGeneral CounselSep 11 '26Sale3.4075,364256,464598,489Sep 15 08:27 PM
Militello JohnFormer OfficerSep 15 '26Proposed Sale3.306,89722,730Sep 15 04:50 PM
Militello JohnFormer OfficerSep 14 '26Proposed Sale3.326,85722,731Sep 14 03:25 PM
Wilson MartinOfficerSep 11 '26Proposed Sale3.4075,364256,486Sep 11 04:57 PM
Militello JohnFormer OfficerSep 11 '26Proposed Sale3.408,92330,368Sep 11 04:55 PM
Wilson MartinGeneral CounselAug 18 '26Sale3.386312,133673,853Aug 20 05:30 PM
Shah GauravCEOAug 18 '26Sale3.382,2937,7531,056,594Aug 20 05:25 PM
Shah GauravOfficerAug 18 '26Proposed Sale3.382,2937,754Aug 18 03:49 PM
Wilson MartinOfficerAug 18 '26Proposed Sale3.386312,134Aug 18 03:47 PM
Militello JohnFormer OfficerAug 18 '26Proposed Sale3.381,2524,234Aug 18 03:43 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-101.0800.8601.0830.0018.208
2026Q12026-05-07-0.420-0.407-0.4240.000.0013
2025Q42026-02-26-0.380-0.443-0.3810.000.0013
2025Q32025-11-06-0.450-0.496-0.4510.000.3114
2025Q22025-08-07-0.620-0.548-0.6210.000.0015
2025Q12025-05-08-0.560-0.611-0.5570.006.2314
2024Q42025-02-27-0.620-0.718-0.6190.000.0315
2024Q32024-11-07-0.710-0.750-0.7090.000.0015
2024Q22024-08-05-0.740-0.722-0.7430.000.0013
2024Q12024-05-06-0.660-0.673-0.6630.000.0012
2023Q42024-02-26-0.640-0.779-0.6390.000.0011
2023Q32023-11-06-0.750-0.814-0.7490.000.0012
2023Q22023-08-10-0.820-0.809-0.8160.000.0010
2023Q12023-05-04-0.730-0.829-0.7340.000.0013
2022Q42023-02-27-0.920-0.798-0.9150.000.1115
2022Q32022-11-03-0.870-0.786-0.8720.000.0014

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.580-1.649-1.5770.000.00
2020FY-2.520-1.919-2.5230.000.00
2021FY-2.670-2.644-2.6740.000.00
2022FY-3.260-3.078-3.2560.000.09
2023FY-2.920-3.065-2.9230.000.00
2024FY-2.730-2.751-2.7290.000.02
2025FY-2.010-2.054-2.0100.000.00
2026FY--0.130--1.11
2027FY--1.364--11.27
2028FY--1.085--28.60
2029FY--0.802--92.42
2030FY--0.276--206.82

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-2510000.200.002.00
2026Q3S2026-08-3110020.200.002.00
2026Q3S2026-08-169020.220.002.00
2026Q3S2026-08-1111020.390.002.24
2026Q3S2026-07-2211000.700.003.00
2026Q3S2026-06-1511200.700.003.00
2026Q3S2026-06-1011210.700.003.00
2026Q3S2026-06-0311230.700.003.00
2026Q3S2026-05-0810220.770.003.00
2026Q3S2026-04-0110120.320.002.24
2026Q3S2026-03-2710210.550.002.25
2026Q3S2026-03-0210200.640.002.25
2026Q3S2026-02-279100.690.002.24
2026Q3S2026-02-186001.490.004.24

Estimate history

EPS, annual-11.524-1.892-1.577-2.523-2.674-3.256-2.923-2.729-2.008-0.1801
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.743-0.709-0.619-0.557-0.621-0.451-0.381-0.4241.076
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual1.69945.14554.76960.99664.50679.12190.282106.454108.32109.539
Period201720182019202020212022202320242025MRQ
Shares, quarterly90.95791.117106.454106.754107.884108.209108.32109.124109.539
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A9.7111.039.387.106.275.371.150.430.33
Gross Profit-9.71-11.03-9.38-7.10-6.27-5.37-1.15-0.43-0.33
Selling, General and Administrative Excl. Other182.18217.49263.83252.56218.08161.97134.8676.9265.53
Research and Development118.98135.71165.22180.97161.53120.20108.8459.4053.27
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-191.88-228.52-273.20-259.66-224.34-167.35-136.00-77.35-65.86
Interest Expense1.891.891.891.881.862.986.975.966.04
Unusual Expense-0.013.331.880.000.000.001.900.005.30
Net Income Before Taxes-8.63-223.12-258.75-245.59-222.36-170.07-139.70-77.52-74.70
Income Taxes8.620.000.000.00-0.50-1.000.00-0.25-0.19
Consolidated Net Income-17.25-223.12-258.75-245.59-221.86-169.07-139.70-77.27-74.52
Net Income From Continuing Operations-17.25-223.12-258.75-245.59-221.86-169.07-139.70-77.27-74.52
Net Income-17.25-223.12-258.75-245.59-221.86-169.07-139.70-77.27-74.52
EPS (Recurring)-0.15-1.99-2.72-2.92-3.26-2.67-2.50-1.58-1.80
EPS (Basic, Before Extraordinaries)-0.16-2.01-2.73-2.92-3.26-2.67-2.52-1.58-1.89
EPS (Diluted)-0.18-2.01-2.73-2.92-3.26-2.67-2.52-1.58-1.89
EBITDA-182.18-217.49-263.83-252.56-218.08-161.97-134.86-76.92-65.53
Non-Operating Income (Expense)185.1310.6218.2215.943.840.265.175.792.49
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense31.7837.0643.9239.4124.5021.3418.579.7613.60
Shares Outstanding109.54108.32106.4590.2879.1264.5161.0054.7745.14
Market Capitalization268.95268.951,336.662,702.061,540.731,406.783,281.841,246.54657.31

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.102.152.223.242.542.992.362.39
Gross Profit-2.10-2.15-2.22-3.24-2.54-2.99-2.36-2.39
Selling, General and Administrative Excl. Other44.8246.3741.8149.1865.1461.4060.3367.03
Research and Development28.2230.1728.0432.5541.0434.0835.8840.79
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-46.92-48.51-44.03-52.42-67.68-64.39-62.69-69.42
Interest Expense0.470.470.470.470.470.470.470.47
Unusual Expense0.000.10-0.04-0.073.570.090.00-0.10
Net Income Before Taxes131.84-47.59-42.54-50.33-68.92-61.33-60.33-66.72
Income Taxes8.620.000.000.000.000.000.000.00
Consolidated Net Income123.21-47.59-42.54-50.33-68.92-61.33-60.33-66.72
Net Income From Continuing Operations123.21-47.59-42.54-50.33-68.92-61.33-60.33-66.72
Net Income123.21-47.59-42.54-50.33-68.92-61.33-60.33-66.72
EPS (Recurring)1.08-0.42-0.38-0.45-0.60-0.56-0.62-0.71
EPS (Basic, Before Extraordinaries)1.09-0.42-0.38-0.45-0.62-0.56-0.62-0.71
EPS (Diluted)1.08-0.42-0.38-0.45-0.62-0.56-0.62-0.71
EBITDA-44.82-46.37-41.81-49.18-65.14-61.40-60.33-67.03
Non-Operating Income (Expense)179.231.491.922.492.803.622.843.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.428.496.119.7610.8610.3311.0911.25
Shares Outstanding109.54109.12108.32108.21107.88106.75106.4591.12
Market Capitalization268.95388.68379.86351.77263.96711.221,336.661,680.32

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments188.93372.34373.18356.39388.74482.72304.12205.7318.14
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.815.855.057.673.324.633.643.360.81
Total Current Assets192.73378.18378.22364.06392.06487.35307.75209.0918.95
Net Property, Plant & Equipment71.5983.3287.5977.6472.3570.6431.352.030.98
Total Investments and Advances1.341.3635.6944.621.341.571.528.840.21
Intangible Assets64.3064.3064.3064.8830.8230.8231.0430.820.00
Other Assets0.480.530.530.610.460.460.460.550.00
Total Assets330.45527.70566.34551.81497.02590.82372.12251.3120.15
Short Term Debt Incl. Current Port. of LT Debt2.922.862.722.512.557.140.960.000.00
Accounts Payable0.000.000.000.000.000.000.000.000.00
Other Current Liabilities27.2937.8345.7936.6619.6125.4717.3515.374.52
Total Current Liabilities30.2140.6848.5139.1722.1732.6218.3115.374.52
Long Term Debt21.9622.6422.3320.3620.0554.5546.4941.450.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities1.061.142.942.600.080.140.020.460.11
Total Liabilities53.2364.4773.7762.1242.3087.3164.8257.284.63
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.0041.47
Common Equity277.22463.23492.57489.69454.72503.52307.30194.04-25.95
Total Shareholders Equity277.22463.23492.57489.69454.72503.52307.30194.0415.52
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity277.22463.23492.57489.69454.72503.52307.30194.0415.52
Total Liabilities & Stockholders Equity330.45527.70566.34551.81497.02590.82372.12251.3120.15
Book Value Per Share2.564.355.466.197.058.255.614.30-15.27
Tangible Book Value Per Share1.973.754.745.376.577.755.043.62-15.27
Full-Time Employees20229926824015191573920
Price to Book Ratio0.733.474.993.613.106.644.063.451.39
Return on Assets-52.00-47.30-43.93-42.31-31.08-29.02-24.79-42.21-26.14
Return on Equity-60.27-54.14-50.01-46.98-35.29-34.46-30.83-61.64-44.15
Return on Invested Capital-74.58-53.25-47.70-43.50-35.61-25.03-21.84-31.64-126.16
Quick Ratio6.389.307.809.2917.6914.9416.8113.604.19
Current Ratio6.389.307.809.2917.6914.9416.8113.604.19

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-17.25-223.12-258.75-245.59-221.86-169.07-139.70-77.27-74.52
Depreciation9.7111.039.387.106.275.371.150.430.33
Other Funds (Non Cash)-150.5030.3537.7330.1231.3845.9248.8915.9116.02
Funds from Operations-158.04-181.75-211.64-208.37-184.22-117.78-89.67-60.94-58.17
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-12.24-8.301.8213.325.90-3.599.47-3.734.38
Cash from Operating Activities-170.28-190.05-209.82-195.06-178.31-121.36-80.20-64.66-53.79
Capital Expenditures-0.13-0.44-5.86-16.47-8.62-7.71-29.06-23.27-1.45
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.0042.730.000.000.0076.37
Purchase or Sale of Investments183.79104.21137.57-81.59-103.4326.57-67.53-15.74-79.81
Purchase of Investments-147.46-276.55-245.89-390.92-376.33-245.88-209.34-184.30-141.09
Sale Or Maturity of Investments331.25380.76383.45309.33272.89272.44141.81168.5661.28
Other Uses0.000.000.000.000.000.000.000.00-0.38
Other Sources178.190.000.000.000.000.000.000.000.00
Cash from Investing Activities361.85103.77131.71-98.07-69.3318.85-96.59-39.01-5.27
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.150.00185.74208.40155.2937.68283.84178.13153.50
Repurchase of Common Pref Stock0.000.000.000.00-0.050.00-0.070.00-0.67
Sale of Common Pref Stock0.150.00185.74208.40155.3437.68283.91178.13154.17
Proceedsfrom Stock Options0.000.00182.53206.16154.7026.35281.35178.10154.02
Issuance or Reduction of Debt, Net0.010.040.100.140.170.205.560.000.00
Change in Long Term Debt-0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.070.150.000.000.000.00-0.85-0.340.00
Other Financing Activities Uses-0.07-0.070.000.000.000.00-0.85-0.340.00
Cash from Financing Activities0.090.18185.83208.54155.4637.88288.55177.79153.50
Net Change in Cash191.66-86.10107.72-84.58-92.18-64.63111.7674.1294.44
Free Cash Flow-170.40-190.49-215.68-211.53-186.93-129.08-109.26-87.93-55.24
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments283.75144.38188.93222.76271.49318.16
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets5.805.453.814.925.666.33
Total Current Assets289.55149.83192.73227.68277.15324.49
Net Property, Plant & Equipment67.4269.4571.5974.1777.6480.39
Total Investments and Advances1.341.341.341.361.361.36
Intangible Assets64.3064.3064.3064.3064.3064.30
Other Assets0.480.480.480.520.520.51
Total Assets423.10285.41330.45368.03420.98471.07
Short Term Debt Incl. Current Port. of LT Debt2.982.922.922.912.892.88
Accounts Payable0.000.000.000.000.000.00
Income Tax Payable8.62-----
Other Current Liabilities19.7221.5427.2928.2640.5132.44
Total Current Liabilities31.3224.4730.2131.1743.4035.31
Long Term Debt21.8221.8421.9622.1322.3122.48
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.131.061.061.061.061.14
Total Liabilities54.2747.3753.2354.3666.7758.93
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity368.83238.04277.22313.67354.21412.14
Total Shareholders Equity368.83238.04277.22313.67354.21412.14
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity368.83238.04277.22313.67354.21412.14
Total Liabilities & Stockholders Equity423.10285.41330.45368.03420.98471.07
Book Value Per Share3.372.182.562.903.283.86
Tangible Book Value Per Share2.781.591.972.302.693.26
Full-Time Employees--202---
Price to Book Ratio0.731.401.210.990.631.53
Return on Assets-4.09-55.36-52.00-63.25-59.33-53.17
Return on Equity-4.77-64.41-60.27-74.88-69.65-60.45
Return on Invested Capital31.54-18.31-14.22-14.99-18.30-14.11
Quick Ratio9.246.126.387.306.399.19
Current Ratio9.246.126.387.306.399.19

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income123.21-47.59-42.54-50.33-68.92-61.33
Depreciation2.102.152.223.242.582.99
Other Funds (Non Cash)-171.417.475.298.168.648.26
Funds from Operations-46.10-37.98-35.03-38.93-57.70-50.09
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital6.48-7.420.19-11.508.72-5.71
Cash from Operating Activities-39.61-45.39-34.84-50.43-48.98-55.80
Capital Expenditures-0.01-0.09-0.080.05-0.05-0.36
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments36.1817.5436.5193.5631.81-57.67
Purchase of Investments-14.82-48.71-54.49-29.44-52.69-139.93
Sale Or Maturity of Investments51.0066.2591.00123.0084.5082.26
Other Uses0.000.000.000.000.000.00
Other Sources178.190.000.000.000.000.00
Cash from Investing Activities214.3617.4536.4293.6231.76-58.03
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.150.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.150.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.00-0.000.000.010.010.01
Change in Long Term Debt-0.00-0.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.00-0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.070.210.00
Other Financing Activities Uses0.000.000.00-0.070.000.00
Cash from Financing Activities0.15-0.000.00-0.060.230.01
Net Change in Cash174.90-27.951.5843.13-16.99-113.83
Free Cash Flow-39.62-45.49-34.92-50.37-49.03-56.17

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3015.67%16.2M103.7M1.84M
2026-10-1515.71%16.3M103.7M1.75M
2026-09-3014.52%15.0M103.7M1.74M
2026-09-1514.32%14.8M103.7M1.97M
2026-08-3114.21%14.7M103.6M2.19M
2026-08-1413.90%14.4M103.6M2.33M
2026-07-3115.02%15.5M103.2M2.39M
2026-07-1516.06%16.6M103.2M2.54M
2026-06-3017.53%18.2M103.6M2.59M
2026-06-1521.14%21.9M103.6M3.13M
2026-05-2921.67%22.4M103.6M3.26M
2026-05-1520.23%20.9M103.6M3.37M
2026-04-3021.01%21.5M102.6M3.35M
2026-04-1518.61%19.1M102.5M3.41M
2026-03-3118.40%18.6M101.0M3.35M
2026-03-1314.55%14.7M101.0M2.41M
2026-02-2713.85%14.0M101.0M2.19M
2026-02-1314.36%14.5M100.7M2.10M
2026-01-3013.96%13.9M99.7M2.10M
2026-01-1513.43%13.4M99.7M2.04M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.600.284.0045130.000.607-0.0310.001
call5.000.000.050.033.0391420.000.107-0.0120.001
call7.500.000.050.004.1910.000.000.086-0.0140.001
put2.500.050.500.353.21286.000.00-0.393-0.0300.001
put5.002.003.200.007.8380.000.00-0.893-0.0120.001
put7.504.505.700.009.2990.000.00-0.914-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09144Filing for proposed sale of securities under Rule 144.SEC
2026-11-09144Filing for proposed sale of securities under Rule 144.SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-068-KCurrent report2026-09-30SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-0225-NSESEC
2026-08-278-KCurrent report2026-08-21SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100127.81K1
2026-100000
2026-0900256.46K1
2026-0800176.00K6
2026-070000
2026-060000
2026-0500275.03K8
2026-040000
2026-030000
2026-0200122.04K6
2026-0134.40K100
2025-120000
2025-110034.46K4

Institutional holders

Manager% owned
RTW INVESTMENTS, LP16.20%
BlackRock, Inc.9.09%
VANGUARD PORTFOLIO MANAGEMENT LLC5.32%
CITIGROUP INC4.20%
MARSHALL WACE, LLP3.69%
MILLENNIUM MANAGEMENT LLC3.66%
Newtyn Management, LLC3.66%
MAVERICK CAPITAL LTD3.59%
VANGUARD CAPITAL MANAGEMENT LLC3.47%
AQR CAPITAL MANAGEMENT LLC3.10%

Funds

Fund% owned
Diversified Bond Fund16.30%
Touchstone Funds Group Trust-Touchstone Ultra Short Duration Fixed Income Fund9.63%
Global Bond Fund8.35%
Touchstone ETF Trust-Touchstone Ultra Short Income ETF5.24%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.47%
Short Duration Strategic Income Fund2.45%
iShares Russell 2000 ETF2.17%
Short Duration Fund1.86%
Nuveen Quant Small Cap Equity Fund1.58%
VANGUARD STRATEGIC EQUITY FUND1.55%

OakChart. RCKT. Cached 15 minutes.